the SAR1B gene is expressed in many tissues, 20 it remains unclear why its defects impact essentially on intestinal lipid transport. Furthermore, this lack of understanding is accentuated by the presence of the Sar1A GTPase paralog that is 90% identical, differing by only 20 amino acid residues, which may serve to compensate for the lack of the Sar1B protein in CRD. In this context, Sar1B actions were shown to be intriguingly antagonized by Sar1A in the liver. 21 Moreover, no proof-ofprinciple experiments have been performed to examine the specific role of Sar1B in chylomicron assembly and output. Finally, little effort was devoted to explain how SAR1B defects in CRD affect the levels of circulating high-density lipoprotein (HDL).
Therefore, the major aims of the present work are (1) to examine the cause-effect relationship between Sar1B expression and intestinal fat transport; (2) to determine whether SAR1B deletion prevents enterocytes from synthesizing and exporting HDL, which may explain the dramatic decrease in HDL cholesterol in CRD blood circulation; and (3) to understand the cooperation between Sar1A and Sar1B regarding lipid transport.
Materials and Methods
SAR1A and SAR1B genes were abrogated in Caco-2/15 enterocytes through the zinc-finger nuclease system. Thereafter, lipid synthesis, de novo Apo biogenesis, and lipoprotein output were assessed using radioactive precursors ([14C]-oleic acid, [35S]-methionine). Materials and Methods are available in the online-only Data Supplement.
Results

SAR1B Deletion and Caco-2/15 Cell Integrity
To investigate the impact of Sar1B on lipid synthesis, apolipoprotein biogenesis, and lipoprotein delivery, we generated intestinal epithelial Caco-2/15 cells with specific disruption of SAR1B using appropriate CompoZn knockout zinc finger nuclease constructs. Quantitative reverse transcriptase (qRT)-polymerase chain reaction ( Figure 1A ) and immunoblotting ( Figure 1B) analyses showed complete depletion of SAR1B at both the mRNA and protein levels in differentiated Caco-2/15 cells, thereby providing us with a robust cellular model for the investigation of fat absorption in the manner of CRD enterocytes. Noteworthy, Caco-2/15 cell integrity was not disturbed by genetic manipulation and by the abovementioned experimental conditions (eg, presence of OA as a substrate for 24 hours and absence of serum in the culture medium) because assessment of cell viability by trypan blue exclusion and cytosolic lactic dehydrogenase enzyme leakage to the culture medium did not show any differences between control (empty vector) and Sar1B −/− cells (results not shown). Additionally, measurement of transepithelial resistance with and without serum did not disclose any significant perturbation ( Figure IA in the online-only Data Supplement). Finally, analysis of the proapoptotic factors apoptosis inducing factor, Bax, and Bcl2 by Western blot did not reveal any sign of cell death ( Figure IB in the online-only Data Supplement). Thus, it could be concluded that the zinc finger gene silencing technique efficiently abrogated the Sar1B gene expression without exerting any cytotoxic effects on Caco-2/15 cells. Moreover, our experimental conditions seem appropriate to examine the cause-effect relationship between Sar1B expression and chylomicron output.
De Novo Lipid Synthesis
To determine the effects of SAR1B deletion on lipid esterification and secretion, control and Sar1B −/− cells were cultured with [ 14 C]-OA in serum-free EMEM (Eagle's minimum essential medium) for 24 hours. Monitoring of data in cellular content revealed significantly less cholesteryl ester and phospholipids (P<0.05) in Sar1B −/− cells ( Figure 2A ). Lipid changes were also evidenced in the basolateral medium of Sar1B −/− cells (compared with controls) in view of the decreased total lipid amount (P<0.01) and the dramatic reduction in triglyceride secretion (P<0.001) in addition to cholesteryl ester and phospholipids ( Figure 2B ). Noteworthy, to exclude the influence of severe experimental conditions (eg, incubation for 24 hours in serum-free medium), control, Sar1B 
Apolipoprotein Biogenesis
To examine the effect of SAR1B knockout (Sar1B −/− ) on apolipoprotein production, control and Sar1B −/− cells were cultured with [ 35 S]-methionine for 24 hours, and the delivery of newly synthesized apolipoprotein to the medium was analyzed by NaDodSO 4 -PAGE after immunoprecipitation. As noted in Figure 2C, Figure 2D ).
Lipoprotein Secretion
To next evaluate the extent of interference caused by SAR1B ablation in enterocyte lipid transport function, cells were incubated with [
14 C]-OA for 24 hours before the isolation of triglyceride-rich lipoproteins. Although a significant decline was noted in chylomicron (≈35%; P<0.05) and very low-density lipoprotein (≈63%; P<0.01) secretion in Sar1B −/− versus control cells ( Figure 2E ), the expected total absence of triglyceride-rich lipoprotein export was not observed, as is the case for patients with CRD.
Effect of SAR1B Deletion on SAR1A Expression
In view of the residual chylomicron secretion observed in response to SAR1B abrogation, we assessed the expression of SAR1A homolog to evaluate potential compensation. According to our data, SAR1B silencing induces upregulation of SAR1A expression at the gene ( Figure 3A ) and protein ( Figure 3B ) levels.
SAR1 Double Knockout and Consequences on Lipid Production, Lipoprotein Secretion, and Apolipoprotein Biogenesis
In view of SAR1A induction on SAR1B disruption, we engineered a double knockout through transfection of Sar1B
−/− cells with CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) KO constructs against SAR1A to yield Sar1AB −/− cells. Verification by qRT-polymerase chain reaction ( Figure 3C ) and immunoblotting ( Figure 3D ) illustrates the complete disruption of both SAR1 paralogs, which afford us with an unprecedented model to genuinely dissect the biochemical bases of CRD.
The following set of assays deals with the consequence of double SAR1 ablation on lipid manufacturing. Control and Sar1AB −/− cells were grown in serum-free EMEM supplemented with labeled [ ]-methionine precursor, we noted the dramatic synthesis/ output reduction of de novo apolipoprotein B-48 ( Figure 4C ) and apolipoprotein A-I ( Figure 4D ). We then addressed the critical issue whether the ablation of the 2 SAR1 homologs causes a more pronounced negative effect on lipoprotein excretion. Thus, control and Sar1AB −/− cells were cultured in the presence of labeled OA, and lipoprotein secretion was monitored. Figure 4E reveals the evident inability of Sar1AB −/− cells to secrete chylomicron and very low-density lipoprotein.
Because mature human enterocytes produce only apolipoprotein B-48 as the major apolipoprotein of chylomicron, our aforementioned de novo experiments focused exclusively on this apolipoprotein form. However, the Caco-2/15 cell line produces both apolipoproteins B-100 and B-48. It was, therefore, felt that some caution should be exercised in analyzing To approach some of the mechanisms implicated in the derangements of intracellular triglyceride-rich lipoprotein assembly, we analyzed the protein expression of intestinal and L-FABP (liver fatty acid-binding protein; permitting the binding and transport of mainly fatty acids through the cytosol to cell organelles), as well as MTTP (an obligatory protein for the formation of chylomicron and very low-density lipoprotein particles). Both monogenic SAR1B deletion and SAR1AB double knockout downregulated intestinal FABP with a greater intensity in favor of combined SAR1AB deletion ( Figure 5A and 5B). On the contrary, L-FABP protein level was only slightly lowered in Sar1B −/− cells ( Figure 5C ) and significantly depressed in Sar1AB −/− cells ( Figure 5D ), unlike MTTP expression, which was upregulated in both cases ( Figure 5E and 5F ).
Because patients with CRD disclose low levels of circulating HDL cholesterol, we performed new sets of experiments with micellar [ Figure 6C ) compared with their controls. To shed light on the defective cholesterol efflux by SAR1 deletion, we analyzed the ABCA1 (ATP-binding cassette subfamily A member 1)-a basolateral membrane protein essential for the initial step of HDL biogenesis by facilitating the efflux of cellular free cholesterol to extracellular lipid-free apolipoprotein A-I-thereby forming nascent HDL particles. Evidently, the deletion of SAR1B ( Figure 6E ) and SAR1AB ( Figure 6F ) resulted in decreased ABCA1 expression.
Our de novo synthesis experiments showed a decline in apolipoprotein A-I biogenesis. Because liver X receptor α is a negative modulator of apolipoprotein A-I, it was, therefore, deemed reasonable to examine the liver X receptor α expression in response to SAR1B deletion and SAR1AB double knockout ( Figure IV in the online-only Data Supplement). We first analyzed apolipoprotein A-I protein and gene expression and confirmed its more severe downregulation by the double knockout compared with the SAR1B deletion ( Figure IVA through IVC in the online-only Data Supplement). However, we could not identify significant changes in liver X receptor α ( Figure IVD and IVE in the online-only Data Supplement).
The summary of our experiments shows that suppression of both paralogs is required to produce the effects observed in patients with CRD (Table I in 
Discussion
Extensive efforts during the past 3 decades have improved our knowledge of the physiological events underlying alimentary lipid transport and the intraenterocyte phase of chylomicron formation by the small intestine. For example, lessons from the CRD inborn absorptive disorder have highlighted the primordial importance of Sar1b GTPase-an obligatory component of COPII vesicles that buds from the endoplasmic reticulum to transport proteins and lipoproteins to the Golgi apparatus. However, major issues remain unsolved regarding the causeeffect relationship between SAR1B and regulation of intestinal triglyceride-rich lipoprotein packaging and secretion, SAR1B cooperation with SAR1A, and Sar1B role in HDL biogenesis. In the present work, our experiments showed that total silencing of SAR1B lessens but not extinguishes the output of triglyceriderich lipoproteins as is the case for patients with CRD. It is only through the combined SAR1B and SAR1A depletion that chylomicron delivery was dramatically eliminated. Additionally, SAR1 abrogation modulates the protein expression of intestinal FABP, L-FABP, and MTTP while decreasing ABCA1, which affected enterocyte cholesterol efflux and HDL generation.
The human Caco-2/15 cell line has the property to spontaneously differentiate into a cell monolayer with characteristics typical of small-intestinal epithelium, such as brush-border microvilli, tight junctions and vectorial transport of both cations and anions concomitant with raised synthesis, and secretion of apolipoproteins. [22] [23] [24] To closer mimic the physiological conditions of the intestine in vivo, Caco-2/15 cells are cultured on permeable filter inserts, which improves their morphological and functional differentiation, while granting access to both apical and basolateral sides of the bipolar intestinal epithelium. This remarkable intestinal model is regarded as the most appropriate for the investigation of gut absorption and interactions, nutrition, toxicology food microbiology, bioavailability tests, and screening of drug permeability in discovery programs. For example, studies from our laboratory showed that Caco-2/15 monolayers are fully appropriate for the study of lipid/lipoprotein homeostasis. 10, [25] [26] [27] [28] [29] [30] [31] [32] [33] Although crucial mechanisms for multiple genetic, functional, and regulatory processes have been learnt from the Caco-2/15 cell line, differences in Sar1b −/− -mediated lipid/lipoprotein metabolism may exist with respect to normal tissue and primary intestinal cells. Therefore, before drawing any definitive conclusions, additional studies are required using the organotypic culture of biological specimens from patients with CRD or with mouse models with SAR1B gene knockout.
Previously, our studies evidenced the expression pattern of SAR1B, 20 the regulatory role of the latter for Sar1B-cholesterol transport and metabolism, 34 and how its overexpression in animals under high-fat diet elicited cardiometabolic traits as revealed by incremental weight gain, fat deposition, dyslipidemia, hepatic steatosis, insulin insensitivity, and intestinal fat absorption. 35 In this investigation, our experiments provided the proof of concept relative to the role of SAR1B in chylomicron export from intestinal epithelial cells via the manifestation of markedly reduced chylomicron secretion in response to SAR1B silencing. However, the combined depletion of SAR1B and SAR1A was necessary in vitro to mimic the in vivo ]-methionine for 24 h, and the synthesis of newly apolipoprotein B-48 (C) and apolipoprotein A-I (D) in the cell and in media were assayed by SDS-PAGE after immunoprecipitation. Chylomicrons (CMs) and very low-density lipoprotein (VLDL; E) were separated from the basolateral media by ultracentrifugation, and radioactivity was counted. Results represent the means±SEM of 3 independent experiments in triplicate. *P<0.05, **P<0.01, ***P<0.001 vs controls. December 2017 CRD, which results in lipid malabsorption syndrome with steatorrhea, chronic diarrhea, and growth retardation in young patients. 11, 16 Our interesting data are in line with the recently developed zebrafish model of SAR1B deficiency based on antisense oligonucleotide knockdown.
36 SAR1B deficiency led not only to intestinal fat malabsorption but also to developmental deficits in multiple organs. 36 The authors mentioned that the combined depletion of SAR1A and SAR1B resulted in phenotypes similar to SAR1B knockdown but with more severe phenotypes.
The Caco-2/15 cells do not seem to recapitulate the severity of the phenotype observed in patients with CRD with SAR1B mutations because abrogation of SAR1B in our experiments did not nullify the secretion of chylomicron and very low-density lipoprotein. Using the UniGene EST profile database, Georges et al 37 found the level of Sar1b mRNA to be ≈3 higher than Sar1A mRNA in the human intestine. They were also able to show that even if Sar1A increased 1.5-fold in the duodenal biopsies of patients with CRD, this was insufficient to compensate for the staggering decrease in Sar1B expression. In our hands, control Caco-2/15 cells already express 15% more Sar1A than Sar1B ( Figure 3D ) and Sar1b −/− cells express one third more Sar1A than control cells ( Figure 3B ). These observations may explain the compensatory event of Sar1A described in our study. Other investigators reported that Sar1b mRNA in McArdle-RH7777 hepatocytes was 11.6-fold lower than Sar1A mRNA, and, in these conditions, the overexpression of Sar1B mutant increased Sar1A protein without compensation. 21 Even more, antagonistic effects were observed, such as the abolition of the secretion of apolipoprotein B-48 and apolipoprotein B-100 contained lipoproteins. It is, therefore, possible that the Sar1B mutations cannot be compensated by a sufficient overexpression of Sar1A in the gut of patients with CRD. On the contrary, it is not unrealistic that other factors or gene modifiers occur in the integral intestinal tissue of patients with CRD but are not operational in the Caco-2/15 cell line. In line with this suggestion, Okada et al 38 reported a clinical case of CRD with maternal uniparental disomy of chromosome 7, displaying normal SAR1B gene protein coding sequence. Obviously, further studies are needed to tackle the complex issue concerning the incongruity between experimental in vitro models and patients with CRD, but it is possible that a small amount of triglyceriderich lipoproteins in Caco-2/15 may escape via prechylomicron transport vesicles that do not require Sar1 to bud from the endoplasmic reticulum but rather uses all the COPII proteins and, in particular, Sec24C for docking and fusion with the cis-Golgi. 8, 39, 40 Another possibility is through uncommon secretory pathways, namely the COPI route operation, to circumvent defect of COPII function. 41 It is also important to note that, in our studies, SAR1 silencing affects the protein expression of intestinal FABP and L-FABP. Of note, L-FABP has been shown to initiate and organize the prechylomicron transport vesicle budding machinery. 42 The disruption of SAR1 gene and the accumulation of lipids in enterocytes might have negatively influenced the expression of the 2 cytosolic transporters. Finally, It is also worth noting that despite SAR1B mutations, patients with CRD are note devoid of the ability to absorb lipids and form chylomicrons. As reported in our previous studies, the patients with CRD clearly displayed a small proportion of circulating triglycerides/chylomicron after a fatty meal test. 9, 10 Efforts are definitely required to determine whether this is because of the implication or compensation of SAR1A, and if so, why the Sar1A compensation is so limited in humans compared with experimental Caco-2/15 cells.
The HDL fraction was dramatically affected in patients with CRD because its cholesterol content represented only 22% of control values. 10 The noticeable decline in HDL cholesterol is of significant interest and might be a reflection of limited production of HDL by the small intestine of CRD subjects. Because the intestine is an important site for the synthesis and secretion of HDL and apolipoprotein A-I-the principal apolipoprotein of HDL-while contributing ≈50% of total plasma apolipoproteinA-I, 43 we tested the hypothesis that SAR1B ]-methionine, confirmed the inability of enterocytes to secrete HDL and apolipoprotein A-I, respectively. An alternative hypothesis was that the Sar1B downregulates the protein expression of ABCA1 that facilitates the efflux of cholesterol to apolipoprotein A-I acceptor and leads to HDL formation. Such a scenario was observed in patients with Tangier disease-a disorder associated with mutations in ABCA1-which causes defective cholesterol transfer to an extracellular apolipoprotein A-1 acceptor-a crucial protein for HDL maturation. 44, 45 Our prediction proved to be true because the efflux of cholesterol was low in response to SAR1B silencing and resulted from ABCA1 low expression compared with control cells. Accordingly, Fryer et al 21 showed that SAR1 deficiency lowered the transcripts encoding cholesterol biosynthetic enzymes. All together, these findings may explain the severe hypocholesterolemia phenotype in CRD.
In summary, the present study is the first to report the cause-effect relationship between the SAR1B gene defect and chylomicron secretion failure in intestinal epithelial cells. However, the combined deletion of SAR1B and SAR1A was absolutely necessary to fully inhibit chylomicron delivery to mimic patients with CRD who are only affected by mutations of SAR1B. In addition, absence of SAR1B markedly impaired HDL formation via the reduction of HDL synthesis and cholesterol efflux, which may explain the low levels of circulating HDL in patients with CRD. Because all our experiments have been performed in an intestinal cell model that allows limited extrapolation to humans, additional studies are needed in in vivo conditions.
